Aquinox sets terms for $41M IPO; Compugen shares plunge; Actelion wins fast-track status

@FierceBiotech: GlaxoSmithKline hits the brakes on an anti-inflammatory drug from Galapagos. News | Follow @FierceBiotech

@JohnCFierce: Remember that big Gilead bet on Pharmasset? It paid off and made John Martin a billionaire. Item | Follow @JohnCFierce

@DamianFierce: India's Lupin queues up for a share of the biosimilar boom. Story | Follow @DamianFierce

@EmilyMFierce: Experimental supplement extends lifespan, stops metabolic disease in mice. Article from FierceBiotechResearch | Follow @EmilyMFierce

> Aquinox Pharmaceuticals has set its terms for a $41 million IPO, looking to seal shares at $10 to $12 a share. Story

> Shares of Israel's Compugen ($CGEN) plunged after it sold stock at a discount. Report

> Actelion ($ATLN) says the FDA has granted fast-track status for its diarrhea therapy. Story

> Cell Therapeutics ($CTIC) has launched a Phase III clinical trial, PERSIST-2, to study pacritinib in patients with myelofibrosis. Release

Medical Device News

@FierceMedDev: How to gain new stent sales in a sluggish market: bulk discount deals. Story | Follow @FierceMedDev

@MarkHFierce: For Covidien, a ventilation system wins a CE mark after other product setbacks in the space. More | Follow @MarkHFierce

@MichaelGFierce: New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. Article from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: White noise sleep machines at full volume could cause hearing damage in infants, say researchers. News | Follow @EmilyWFierce

> Abbott and Medtronic are sharing a bulk discount deal to sell stents at 135 hospitals. More

> GE Ventures pours cash into RainDance's $16.5M Series E extension. Story

> BSD bets on new ablation device sales growth in its ongoing Terumo deal. More

Pharma News

@FiercePharma: Best-read over the weekend: Pradaxa, Xarelto makers dispute purported Eliquis safety edge. Piece | Follow @FiercePharma

@TracyStaton: The graph's the thing: Takeda admits to 'inappropriate' drug advertising in Japan. News (sub. req.) | Follow @TracyStaton

@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. Story | Follow @EricPFierce

@CarlyHFierce: Teva's new Copaxone formula could be a hard sell with payers. Article | Follow @CarlyHFierce

> Questcor, short sellers trade attacks. More

> No merger talk here: Novartis just wants to be friends with Roche, chairman says. Story

> Generic makers to FDA: Labeling rule risky for patients, adds $4B in annual costs. News

CRO News

> InVentiv amps up its biosimilar efforts with latest deal. Story

> Report: VC giant Sequoia unloading $50M stake in India's GVK. News

> Quintiles touts its talent as cash rolls in. Article

> Cardialysis taps AG Mednet to handle an ocean of trial data. Story

> MPI's imaging team-up snags a cyclotron as it preps for opening day. Story

> Charles River looks to Exostar for cloud-based data platform. Brief

Biotech IT News

> Google joins genomics alliance as it prepares industry-focused cloud services. News

> Novartis' pitch to join trial data sharing bandwagon gets frosty reception. Story

> U.K. begins trying to rebuild trust in patient database after months of 'confusion, suspicion and anxiety.' Article

> FDA defends itself against accusations its email snooping broke whistleblower laws. Story

> George Washington University to trial 40-Gbps genomics data transfers with NIH. Article

> NIH adds genetic data from Kaiser, UCSF to online resource. Brief

 

Suggested Articles

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets. 

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.